Furthermore, the expression of PD-L1 in cancer cells has been shown to be negatively regulated by PARP1, and conversely, PARP1 inhibition leads to an increase in PD-L1 expression, proposing one possible explanation for the more effective control of tumor growth with the combinatorial treatment compared to PARPi monotherapy [56]. The gene discussed is PARP1; the disease is cancer.